RVPH实时信号 | 通过Getagraph.com最大化利润

购买 109167 min ago

@ $4.65

发出时间: 14 Feb 2024 @ 01:23

回报率: -35.70%

上一信号: Feb 13 - 22:32

上一信号: 出售

回报率: 4.26 %

Live Chart Being Loaded With Signals

Commentary (27 Apr 2024 @ 04:00):

Stats
今日成交量	116 230
平均成交量	294 580
市值	83.48M
EPS	$0 ( 2024-04-04 )
下一个收益日期	( $-0.280 ) 2024-05-20
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-1.810
ATR14	$0.00900 (0.30%)

Insider Trading

Date	Person	Action	Amount	type
2023-11-20	Saxena Parag	Buy	585 366	Pre-Funded Warrant
2023-11-20	Saxena Parag	Buy	585 366	Common Stock Warrant (right to buy)
2023-11-13	Funtleyder Leslie D.	Buy	8 200	Stock Option (right to buy)
2023-11-13	Patel Purav	Buy	8 200	Stock Option (right to buy)
2023-11-13	Saxena Parag	Buy	8 200	Stock Option (right to buy)

INSIDER POWER
100.00
Last 72 transactions
Buy: 9 383 157 \| Sell: 2 515 186

音量相关性

長: 0.01 (neutral)

短: -0.73 (moderate negative)

Signal:(42.937) Neutral

Reviva Pharmaceuticals 相关性

10 最正相关

10 最负相关
ISNS	-0.839
APOP	-0.832

你知道吗？

相关性是描述两个变量之间关系的统计指标。它的取值范围为-1到1，其中-1表示完全负相关（一个变量增加，另一个变量减少），1表示完全正相关（一个变量增加，另一个变量也增加），0表示没有相关性（变量之间没有关系）。

相关性可用于分析任何两个变量之间的关系，而不仅仅是股票。它通常用于金融、经济学、心理学等领域。

Reviva Pharmaceuticals 相关性 - 货币/商品

0.34
( neutral )

0.26
( neutral )

0.00
( neutral )

0.18
( neutral )

-0.36
( neutral )

-0.47
( neutral )

Reviva Pharmaceuticals 财务报表

Annual	2022
营收:	$0
毛利润:	$0 (0.00 %)
EPS:	$-1.250

FY	2022
营收:	$0
毛利润:	$0 (0.00 %)
EPS:	$-1.250

FY	2021
营收:	$0.00
毛利润:	$0.00 (0.00 %)
EPS:	$-0.662

FY	2020
营收:	$0.00
毛利润:	$0.00 (0.00 %)
EPS:	$-1.240

Financial Reports:

No articles found.

Reviva Pharmaceuticals

Reviva Pharmaceuticals Holdings, Inc., a clinical-stage biopharmaceutical company, discovers, develops, and commercializes next-generation therapeutics for diseases targeting unmet medical needs in the areas of central nervous system, respiratory, cardiovascular, metabolic, and inflammatory diseases. The company's lead product candidate is RP5063, which is in Phase III clinical trials for the treatment of schizophrenia, as well as completed Phase I clinical trials to treat bipolar disorder, major depressive disorder, attentiondeficit/hyperactivity disorder, behavioral and psychotic symptoms of dementia or Alzheimer's disease, Parkinson's disease psychosis, attention deficit hyperactivity disorder, pulmonary arterial hypertension, and idiopathic pulmonary fibrosis. It is also developing RP1208 that is in pre-clinical development studies for the treatment of depression and obesity. The company is headquartered in Cupertino, California.